Compare NTZ & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTZ | BOLD |
|---|---|---|
| Founded | 1959 | 2018 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.3M | 36.5M |
| IPO Year | 1998 | 2024 |
| Metric | NTZ | BOLD |
|---|---|---|
| Price | $3.00 | $1.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 2.5K | ★ 374.5K |
| Earning Date | 04-13-2023 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $0.96 |
| 52 Week High | $4.46 | $1.72 |
| Indicator | NTZ | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 65.74 |
| Support Level | $2.59 | $1.12 |
| Resistance Level | $3.17 | N/A |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 71.98 | 57.69 |
Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture and sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private label, and Natuzzi Editions. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.